Indication
Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Free account required
Ask Prognia AI about Adasuve — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.